Effect of KEPI (Ppp1r14c) deletion on morphine analgesia and tolerance in mice of different genetic backgrounds: when a knockout is near a relevant quantitative trait locus

Neuroscience

Volumn 165, Issue 3, 2010, Pages 882-895

  Drgonova, J ^a   Zimonjic, D B ^b   Hall, F S ^a   Uhl, G R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

conditioned place preference; morphine analgesia; morphine reward; morphine tolerance; protein phosphatase 1; quantitative trait locus

Indexed keywords

DNA; MORPHINE SULFATE; MU OPIATE RECEPTOR; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KEPI; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 10; CONTROLLED STUDY; ENZYME ACTIVITY; FETUS; GENE DELETION; GENE FUNCTION; GENE LOCUS; LOCOMOTION; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENE;

ANALGESICS, OPIOID; ANIMALS; CONDITIONING, CLASSICAL; DRUG TOLERANCE; LOCOMOTION; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MORPHINE; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PHOSPHATASE 1; PROTEINS; RECEPTORS, OPIOID, MU; REWARD; SEQUENCE DELETION; SPACE PERCEPTION; THALAMUS;

EID: 72749088539     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.10.007     Document Type: Article

References (88)

1. Arden J.R., Segredo V., Wang Z., Lameh J., and Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 65 (1995) 1636-1645
2. Basile A.S., Fedorova I., Zapata A., Liu X., Shippenberg T., Duttaroy A., Yamada M., and Wess J. Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci U S A 99 (2002) 11452-11457
3. Belknap J.K., Mogil J.S., Helms M.L., Richards S.P., O'Toole L.A., Bergeson S.E., and Buck K.J. Localization to chromosome 10 of a locus influencing morphine analgesia in crosses derived from C57BL/6 and DBA/2 strains. Life Sci 57 (1995) L117-L124
4. Bennett B., Carosone-Link P., Beeson M., Gordon L., Phares-Zook N., and Johnson T.E. Genetic dissection of quantitative trait locus for ethanol sensitivity in long- and short-sleep mice. Genes Brain Behav 7 (2008) 659-668
5. Bergeson S.E., Helms M.L., O'Toole L.A., Jarvis M.W., Hain H.S., Mogil J.S., and Belknap J.K. Quantitative trait loci influencing morphine antinociception in four mapping populations. Mamm Genome 12 (2001) 546-553
6. Berrettini W.H., Ferraro T.N., Alexander R.C., Buchberg A.M., and Vogel W.H. Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet 7 (1994) 54-58
7. Bianchi M., Maggi R., Pimpinelli F., Rubino T., Parolaro D., Poli V., Ciliberto G., Panerai A.E., and Sacerdote P. Presence of a reduced opioid response in interleukin-6 knock out mice. Eur J Neurosci 11 (1999) 1501-1507
8. Bogulavsky J.J., Gregus A.M., Kim P.T., Costa A.C., Rajadhyaksha A.M., and Inturrisi C.E. Deletion of the glutamate receptor 5 subunit of kainate receptors affects the development of morphine tolerance. J Pharmacol Exp Ther 328 (2009) 579-587
9. Bohn L.M., Gainetdinov R.R., Lin F.T., Lefkowitz R.J., and Caron M.G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408 (2000) 720-723
10. Bohn L.M., Lefkowitz R.J., and Caron M.G. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22 (2002) 10494-10500
11. Borgkvist A., Usiello A., Greengard P., and Fisone G. Activation of the cAMP/PKA/DARPP-32 signaling pathway is required for morphine psychomotor stimulation but not for morphine reward. Neuropsychopharmacology 32 (2007) 1995-2003
12. Caenepeel S., Charydczak G., Sudarsanam S., Hunter T., and Manning G. The mouse kinome: discovery and comparative genomics of all mouse protein kinases. Proc Natl Acad Sci U S A 101 (2004) 11707-11712
13. Chakrabarti S., Oppermann M., and Gintzler A.R. Chronic morphine induces the concomitant phosphorylation and altered association of multiple signaling proteins: a novel mechanism for modulating cell signaling. Proc Natl Acad Sci U S A 98 (2001) 4209-4214
14. Chakrabarti S., Wang L., Tang W.J., and Gintzler A.R. Chronic morphine augments adenylyl cyclase phosphorylation: relevance to altered signaling during tolerance/dependence. Mol Pharmacol 54 (1998) 949-953
15. Charlton J.J., Allen P.B., Psifogeorgou K., Chakravarty S., Gomes I., Neve R.L., Devi L.A., Greengard P., Nestler E.J., and Zachariou V. Multiple actions of spinophilin regulate mu opioid receptor function. Neuron 58 (2008) 238-247
16. Chen L., and Huang L.Y. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu opioid. Neuron 7 (1991) 319-326
17. Chung S., Pohl S., Zeng J., Civelli O., and Reinscheid R.K. Endogenous orphaning FQ/nociceptin is involved in the development of morphine tolerance. J Pharmacol Exp Ther 318 (2006) 262-267
18. Cohen P., Alemany S., Hemmings B.A., Resink T.J., Stralfors P., and Tung H.Y. Protein phosphatase-1 and protein phosphatase-2A from rabbit skeletal muscle. Methods Enzymol 159 (1988) 390-408
19. Crawley J.N. Behavioral phenotyping of transgenic and knock out mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835 (1999) 18-26
20. D'amour F., and Smith D. A method for determining loss of pain sensation. J Pharmacol Exp Ther 72 (1941) 74-79
21. Doyle G.A., Furlong P.J., Schwebel C.L., Smith G.G., Lohoff F.W., Buono R.J., Berrettini W.H., and Ferraro T.N. Fine mapping of a major QTL influencing morphine preference in C:57BL/6 and DBA/2 mice using congenic strains. Neuropsychopharmacology 33 12 (2008) 2801-2809
22. Eto M., Karginov A., and Brautigan D.L. A novel phosphoprotein inhibitor of protein type-1 phosphatase holoenzymes. Biochemistry 38 (1999) 16952-16957
23. Ferraro T.N., Smith G.G., Schwebel C.L., Lohoff F.W., Furlong P., Berrettini W.H., and Buono R.J. Quantitative trait locus for seizure susceptibility on mouse chromosome 5 confirmed with reciprocal congenic strains. Physiol Genomics 31 (2007) 458-462
24. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D.B., Cole D.G., Corbett R., Haile C.N., Cooper D.C., Onn S.P., Grace A.A., Ouimet C.C., White F.J., Hyman S.E., Surmeier D.J., Girault J., Nestler E.J., and Greengard P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281 (1998) 838-842
25. Gabra B.H., Bailey C.P., Kelly E., Sanders A.V., Henderson G., Smith F.L., and Dewey W.L. Evidence for an important role of protein phosphatases in the mechanism of morphine tolerance. Brain Res 1159 (2007) 86-93
26. Garzon J., Lopez-Fando A., and Sanchez-Blazquez P. The R7 subfamily of RGS proteins assists tachyphylaxis and acute tolerance at mu-opioid receptors. Neuropsychopharmacology 28 (2003) 1983-1990
27. Garzon J., Rodriguez-Diaz M., Lopez-Fando A., Garcia-Espana A., and Sanchez-Blazquez P. Glycosylated phosducin-like protein long regulates opioid receptor function in mouse brain. Neuropharmacology 42 (2002) 813-828
28. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?. Trends Neurosci 19 (1996) 177-181
29. Gong J.P., Liu Q.R., Zhang P.W., Wang Y., and Uhl G.R. Mouse brain localization of the protein kinase C-enhanced phosphatase 1 inhibitor KEPI (kinase C-enhanced PP1 inhibitor). Neuroscience 132 (2005) 713-727
30. Guang W., Wang H., Su T., Weinstein I.B., and Wang J.B. Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphine-induced analgesia. Mol Pharmacol 66 (2004) 1285-1292
31. Guitart X., Thompson M.A., Mirante C.K., Greenberg M.E., and Nestler E.J. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. J Neurochem 58 (1992) 1168-1171
32. Gutstein H.B., Rubie E.A., Mansour A., Akil H., and Woodgett J.R. Opioid effects on mitogen-activated protein kinase signaling cascades. Anesthesiology 87 (1997) 1118-1126
33. Hall F.S., Drgonova J., Goeb M., and Uhl G.R. Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knock out mice. Neuropsychopharmacology 28 (2003) 1485-1490
34. Hall F.S., Huang S., Fong G.F., and Pert A. The effects of social isolation on the forced swim test in fawn hooded and Wistar rats. J Neurosci Methods 79 (1998) 47-51
35. Hendry I.A., Kelleher K.L., Bartlett S.E., Leck K.J., Reynolds A.J., Heydon K., Mellick A., Megirian D., and Matthaei K.I. Hypertolerance to morphine in G(z alpha)-deficient mice. Brain Res 870 (2000) 10-19
36. Hospital F. Size of donor chromosome segments around introgressed loci and reduction of linkage drag in marker-assisted backcross programs. Genetics 158 (2001) 1363-1379
37. Hospital F. Selection in backcross programmes. Philos Trans R Soc Lond B Biol Sci 360 (2005) 1503-1511
38. Keith D.E., Anton B., Murray S.R., Zaki P.A., Chu P.C., Lissin D.V., Monteillet-Agius G., Stewart P.L., Evans C.J., and von Zastrow M. mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 53 (1998) 377-384
39. Keith D.E., Murray S.R., Zaki P.A., Chu P.C., Lissin D.V., Kang L., Evans C.J., and von Zastrow M. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271 (1996) 19021-19024
40. Kest B., Hopkins E., Palmese C.A., Adler M., and Mogil J.S. Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains. Pharmacol Biochem Behav 73 (2002) 821-828
41. Kim K.S., Lee K.W., Lee K.W., Im J.Y., Yoo J.Y., Kim S.W., Lee J.K., Nestler E.J., and Han P.L. Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. Proc Natl Acad Sci U S A 103 (2006) 3908-3913
42. Ko S.W., Jia Y., Xu H., Yim S.J., Jang D.H., Lee Y.S., Zhao M.G., Toyoda H., Wu L.J., Chatila T., Kaang B.K., and Zhuo M. Evidence for a role of CaMKIV in the development of opioid analgesic tolerance. Eur J Neurosci 23 (2006) 2158-2168
43. Lalonde R., Bensoula A.N., and Filali M. Rotorod sensorimotor learning in cerebellar mutant mice. Neurosci Res 22 (1995) 423-426
44. Laurent P., Becker J.A., Valverde O., Ledent C., de Kerchove d Exaerde A., Schiffmann S.N., Maldonado R., Vassart G., and Parmentier M. The prolactin-releasing peptide antagonizes the opioid system through its receptor GPR10. Nat Neurosci 8 (2005) 1735-1741
45. Leo S., Straetemans R., D'Hooge R., and Meert T. Differences in nociceptive behavioral performance between C57BL/6J, 129S6/SvEv, B6 129 F1 and NMRI mice. Behav Brain Res 190 (2008) 233-242
46. Li S., Lee M.L., Bruchas M.R., Chan G.C., Storm D.R., and Chavkin C. Calmodulin-stimulated adenylyl cyclase gene deletion affects morphine responses. Mol Pharmacol 70 (2006) 1742-1749
47. Liang D., Li X., Lighthall G., and Clark J.D. Heme oxygenase type 2 modulates behavioral and molecular changes during chronic exposure to morphine. Neuroscience 121 (2003) 999-1005
48. Liang D.Y., Shi X., Li X., Li J., and Clark J.D. The beta2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav Brain Res 181 (2007) 118-126
49. Liaw W.J., Zhu X.G., Yaster M., Johns R.A., Gauda E.B., and Tao Y.X. Distinct expression of synaptic NR2A and NR2B in the central nervous system and impaired morphine tolerance and physical dependence in mice deficient in postsynaptic density-93 protein. Mol Pain 4 (2008) 45
50. Liu N.J., vonGizycki H., and Gintzler A.R. Phospholipase Cbeta1 modulates pain sensitivity, opioid antinociception and opioid tolerance formation. Brain Res 1069 (2006) 47-53
51. Liu Q.R., Zhang P.W., Zhen Q., Walther D., Wang X.B., and Uhl G.R. KEPI, a PKC-dependent protein phosphatase 1 inhibitor regulated by morphine. J Biol Chem 277 (2002) 13312-13320
52. Maldonado R., Blendy J.A., Tzavara E., Gass P., Roques B.P., Hanoune J., and Schutz G. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 273 (1996) 657-659
53. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
54. McLaren L., Boyle S., Mason J.O., and Bard J.B. Expression and genomic characterization of protein phosphatase inhibitor-1: a novel marker for mesothelium in the mouse. Mech Dev 96 (2000) 237-241
55. Miyamoto Y., Yamada K., Nagai T., Mori H., Mishina M., Furukawa H., Noda Y., and Nabeshima T. Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor epsilon1 subunit. Eur J Neurosci 19 (2004) 151-158
56. Mogil J.S., and Wilson S.G. Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6 inbred mouse strains: implications for transgenic knock-out studies. Eur J Pain 1 (1997) 293-297
57. Moncada A., Cendan C.M., Baeyens J.M., and Del Pozo E. Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice. Eur J Pharmacol 465 (2003) 53-60
58. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11 (1984) 47-60
59. Narita M., Makimura M., Feng Y., Hoskins B., and Ho I.K. Influence of chronic morphine treatment on protein kinase C activity: comparison with butorphanol and implication for opioid tolerance. Brain Res 650 (1994) 175-179
60. Nestler E.J., and Tallman J.F. Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol Pharmacol 33 (1988) 127-132
61. Newton P.M., Kim J.A., McGeehan A.J., Paredes J.P., Chu K., Wallace M.J., Roberts A.J., Hodge C.W., and Messing R.O. Increased response to morphine in mice lacking protein kinase C epsilon. Genes Brain Behav 6 (2007) 329-338
62. Nitsche J.F., Schuller A.G., King M.A., Zengh M., Pasternak G.W., and Pintar J.E. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 22 (2002) 10906-10913
63. Ozdogan U.K., Lahdesmaki J., Hakala K., and Scheinin M. The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol 497 (2004) 161-171
64. Perez R.G., and Lewis R.M. Regional distribution of DARPP-32 (dopamine- and adenosine 3′,5′-monophosphate-regulated phosphoprotein of Mr = 32,000) mRNA in mouse brain. J Comp Neurol 318 (1992) 304-315
65. Raehal K.M., Schmid C.L., Medvedev I.O., Gainetdinov R.R., Premont R.T., and Bohn L.M. Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. Drug Alcohol Depend 104 3 (2009) 187-196
66. Ragot M. Marker-assisted backcrossing: a practical example Techniques et utilisations des marqueurs moleculaires. Les Cilloques Vol. 72 (1995), INRA, Paris
67. Rodriguez-Munoz M., de la Torre-Madrid E., Gaitan G., Sanchez-Blazquez P., and Garzon J. RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons. Cell Signal 19 (2007) 2558-2571
68. Salmon A.M., Damaj M.I., Marubio L.M., Epping-Jordan M.P., Merlo-Pich E., and Changeux J.P. Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Nat Neurosci 4 (2001) 357-358
69. Sanchez-Blazquez P., Rodriguez-Diaz M., Lopez-Fando A., Rodriguez-Munoz M., and Garzon J. The GBeta5 subunit that associates with the R7 subfamily of RGS proteins regulates mu-opioid effects. Neuropharmacology 45 (2003) 82-95
70. Smith D.J., Leil T.A., and Liu X. Neurotrophin-4 is required for tolerance to morphine in the mouse. Neurosci Lett 340 (2003) 103-106
71. Solecki W., Krowka T., Kubik J., Kaczmarek L., and Przewlocki R. Increased analgesic tolerance to acute morphine in fosB knock-out mice: a gender study. Pharmacol Biochem Behav 90 (2008) 512-516
72. Sora I., Elmer G., Funada M., Pieper J., Li X.F., Hall F.S., and Uhl G.R. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 25 (2001) 41-54
73. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., and Uhl G.R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A 94 (1997) 1544-1549
74. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., and Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415
75. Trang T., Koblic P., Kawaja M., and Jhamandas K. Attenuation of opioid analgesic tolerance in p75 neurotrophin receptor null mutant mice. Neurosci Lett 451 (2009) 69-73
76. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., Greengard P., Herve D., and Girault J.A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A 102 (2005) 491-496
77. Vekovischeva O.Y., Zamanillo D., Echenko O., Seppala T., Uusi-Oukari M., Honkanen A., Seeburg P.H., Sprengel R., and Korpi E.R. Morphine-induced dependence and sensitization are altered in mice deficient in AMPA-type glutamate receptor-A subunits. J Neurosci 21 (2001) 4451-4459
78. Walters C.L., Wang B.C., Godfrey M., Sun D., Funk C.D., and Blendy J.A. Augmented responses to morphine and cocaine in mice with a 12-lipoxygenase gene disruption. Psychopharmacology (Berl) 170 (2003) 124-131
79. Whistler J.L., and von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci U S A 95 (1998) 9914-9919
80. Woolfe G., and MacDonald A.D. The evaluation of the analgesic action of pethidine hydrochloride (demerol). J Pharmacol Exp Ther 80 (1944) 300-307
81. Wu N., Lu X.Q., Yan H.T., Su R.B., Wang J.F., Liu Y., Hu G., and Li J. Aquaporin 4 deficiency modulates morphine pharmacological actions. Neurosci Lett 448 (2008) 221-225
82. Yamawaki K., Ito M., Machida H., Moriki N., Okamoto R., Isaka N., Shimpo H., Kohda A., Okumura K., Hartshorne D.J., and Nakano T. Identification of human CPI-17, an inhibitory phosphoprotein for myosin phosphatase. Biochem Biophys Res Commun 285 (2001) 1040-1045
83. Yokoyama K., Kurihara T., Saegusa H., Zong S., Makita K., and Tanabe T. Blocking the R-type (Cav23) Ca2+ channel enhanced morphine analgesia and reduced morphine tolerance. Eur J Neurosci 20 (2004) 3516-3519
84. Zachariou V., Benoit-Marand M., Allen P.B., Ingrassia P., Fienberg A.A., Gonon F., Greengard P., and Picciotto M.R. Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or Inhibitor 1. Biol Psychiatry 51 (2002) 612-620
85. Zachariou V., Georgescu D., Sanchez N., Rahman Z., DiLeone R., Berton O., Neve R.L., Sim-Selley L.J., Selley D.E., Gold S.J., and Nestler E.J. Essential role for RGS9 in opiate action. Proc Natl Acad Sci U S A 100 (2003) 13656-13661
86. Zeitz K.P., Malmberg A.B., Gilbert H., and Basbaum A.I. Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice. Pain 94 (2001) 245-253
87. Zhang J., Ferguson S.S., Barak L.S., Bodduluri S.R., Laporte S.A., Law P.Y., and Caron M.G. Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci U S A 95 (1998) 7157-7162
88. Zhang L., Yu Y., Mackin S., Weight F.F., Uhl G.R., and Wang J.B. Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J Biol Chem 271 (1996) 11449-11454